Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 75-2402409 (State or Ot ...

OPKO Health, Inc. (OPK) delivered a loss per share of 10 cents in the first quarter of 2025, narrower than the year-ago period’s loss of 12 cents per share. However, the metric was wider than the Zacks Consensus Estimate of a loss of 6 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)OPK’s Revenues in DetailOPKO Health registered revenues of $149.9 million in the first quarter, down 13.7% year over year. The figure missed the Zacks Consensus Estimate by 8.9%.The over ...

For the quarter ended March 2025, OPKO Health (OPK) reported revenue of $149.9 million, down 13.7% over the same period last year. EPS came in at -$0.10, compared to -$0.12 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $164.48 million, representing a surprise of -8.87%. The company delivered an EPS surprise of -66.67%, with the consensus EPS estimate being -$0.06.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

OPKO Health (OPK) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -66.67%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.11 per share when it actually produced earnings of $0.01, delivering a surpr ...

OPKO Health (OPK) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good afternoon and welcome to the UpcoHealth First Quarter twenty twenty five Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead. Speaker1 Thank you, operator. Good afternoon. This is Yvonne Briggs with Allianc ...

Exhibit 99.1 OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (April 30, 2025) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: ● Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReferenc ...

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference’s laboratory testing busin ...

MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants ...

Core Viewpoint - OPKO Health, Inc. has authorized a $100 million increase to its common stock repurchase program, raising the total capacity to $200 million, reflecting the company's belief that its shares are undervalued and demonstrating confidence in its strategic direction [1][2]. Summary by Sections Stock Repurchase Program - The Board of Directors has approved an increase of $100 million to the existing stock repurchase program, bringing the total to $200 million [1]. - Approximately $41 million of OPKO's common stock has already been repurchased since the program's initiation in July 2024 [1]. Management's Perspective - The CEO, Phillip Frost, stated that the share buyback supports the company's strategy and ongoing pipeline advancements while aiming for profitability in the diagnostic segment [2]. - The company plans to repurchase shares through various methods, including open market purchases and block trades, without any obligation to repurchase a specific number of shares [2]. Financial Position - OPKO expects to fund the repurchase program using existing cash and future cash flows, with approximately 671.6 million shares outstanding as of February 24, 2025 [3]. - The total repurchase authorization represents about 14% of the outstanding shares at the current stock price [3]. Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its proprietary technologies and expertise in discovery, development, and commercialization [4].

Labcorp (LH) recently entered into an agreement with OPKO Health, Inc. (OPK) , a multinational biopharmaceutical and diagnostics company, to acquire select assets of the latter’s wholly owned subsidiary, BioReference Health. This acquisition will strengthen Labcorp's position in the oncology industry, expanding its extensive portfolio of diagnostic tests in cancer care. Financial DetailsThe purchase price for the transaction is up to $225 million, including $192.5 million payable at closing and up to $32.5 ...